8:37 AM
 | 
Sep 27, 2018
 |  BC Extra  |  Financial News

F-Prime, Atlas lead Akrevia's $30M series A

Immunotherapy company Akrevia Therapeutics LLC (Cambridge, Mass.) launched with a $30 million series A round co-led by F-Prime Capital Partners and Atlas Venture.

Akrevia’s Aklusion platform enables biological molecules such as...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >